TG Therapeutics (TGTX) Misses Q4 EPS by 12c

TG Therapeutics (NASDAQ: TGTX) reported Q4 EPS of ($0.39), $0.12 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $80 thousand versus the consensus estimate of $1.83 million.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• RBC bullish on Kraft Heinz, sees return to growth in 2027
• The Bancorp (TBBK) PT Lowered to $75 at Piper Sandler
• Wall Street on Fed rate hike: 'As hawkish as it gets'